- Home
- CHRO vs IMRN Comparison
CHRO vs IMRN Comparison
Compare CHRO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- IMRN
- Stock Information
- Founded
- CHRO 2002
- IMRN 1994
- Country
- CHRO United States
- IMRN Australia
- Employees
- CHRO N/A
- IMRN N/A
- Industry
- CHRO
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- IMRN Health Care
- Exchange
- CHRO Nasdaq
- IMRN Nasdaq
- Market Cap
- CHRO 10.7M
- IMRN 10.1M
- IPO Year
- CHRO 2024
- IMRN N/A
- Fundamental
- Price
- CHRO $1.45
- IMRN $1.75
- Analyst Decision
- CHRO Strong Buy
- IMRN Strong Buy
- Analyst Count
- CHRO 1
- IMRN 1
- Target Price
- CHRO N/A
- IMRN $5.00
- AVG Volume (30 Days)
- CHRO 8.2K
- IMRN 13.7K
- Earning Date
- CHRO 03-27-2025
- IMRN 04-15-2025
- Dividend Yield
- CHRO N/A
- IMRN N/A
- EPS Growth
- CHRO N/A
- IMRN N/A
- EPS
- CHRO N/A
- IMRN N/A
- Revenue
- CHRO N/A
- IMRN $4,048,286.00
- Revenue This Year
- CHRO N/A
- IMRN N/A
- Revenue Next Year
- CHRO N/A
- IMRN N/A
- P/E Ratio
- CHRO N/A
- IMRN N/A
- Revenue Growth
- CHRO N/A
- IMRN 82.90
- 52 Week Low
- CHRO $0.45
- IMRN $1.70
- 52 Week High
- CHRO $3.80
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- CHRO 43.38
- IMRN 41.07
- Support Level
- CHRO $1.34
- IMRN $1.73
- Resistance Level
- CHRO $2.00
- IMRN $2.09
- Average True Range (ATR)
- CHRO 0.17
- IMRN 0.14
- MACD
- CHRO -0.02
- IMRN 0.00
- Stochastic Oscillator
- CHRO 16.58
- IMRN 10.26
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.